Key facts
- This page summarizes Stefanie Johns's Form 4 filing for Hoth Therapeutics, Inc. (HOTH).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 18 Mar 2022, 16:15.
Stefanie Johns - 16 Mar 2022 Form 4 Insider Report for Hoth Therapeutics, Inc. (HOTH)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- HOTH
- Reported as of
- 16 Mar 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jane H. Springer as Attorney-In-Fact for Stefanie Johns
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Stefanie Johns filed Form 4 for Hoth Therapeutics, Inc. (HOTH) on 18 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HOTH
transaction
Derivative
Options
Award
- Transaction value
- $0
- Shares
- +250,000
- Change %
- Price
- $0.000000
- Shares after
- 250,000
- Date
- 16 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.5910
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options were used pursuant to the Issuer's 2018 Equity Incentive Plan and vested in full upon grant.